Published today25 Jul 2023 22:08
This was published today, so likely get an Rns tomorrow.
Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models.
Conclusion
F-73 is a new structurally distinct antimicrobial drug with a unique mechanism of action which has the potential to be an effective and safe candidate for the topical treatment of microbial infections. In this study, XF-73 was shown to have good in vitro activity against a number of S. aureus isolates, including multidrug-resistant strains, with efficacy superior or comparable to that of the concurrently tested antibacterial drugs; and the XF-73 dermal formulation also demonstrated effective inhibition of antibiotic-resistant bacteria in two models of superficial skin infection, including a high-level mupirocin-resistant strain that was virtually unresponsive to mupirocin. Preliminary morphological studies suggest that the unique mechanism of action of XF-73 may be related to an initial interaction with the bacterial cell wall, followed by a subsequent interaction with the the bacterial cell membrane which affects the cell membrane integrity which could increase its permeability, explaining the release of important intracellular components and ultimately bacterial death without causing bacterial lysis. However, the precise molecular mechanism of the interaction between XF-73 and bacterial membranes is not yet fully understood and will be the focus of future research.
Sign In
Follow the stocks
